Current Liabilities
Accrued Expenses
Neurocrine Biosciences Accrued Expenses decreased by 36.6% to $81.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42.1%, from $57.50M to $81.70M. Over 3 years (FY 2022 to FY 2025), Accrued Expenses shows an upward trend with a 20.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
A steady balance is normal, but a rapid increase could indicate rising operational costs or delays in vendor invoicing.
Detailed definition
This represents liabilities for expenses that have been incurred but not yet invoiced or paid, such as utilities, profes...
Peer comparison
Standard current liability found in almost all corporate balance sheets.
Metric ID:
accrued_expensesHistorical Data
12 periods
| Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $72.80M | $68.60M | $86.20M | $42.60M | $59.80M | $77.10M | $107.50M | $57.50M | $84.60M | $105.10M | $128.80M | $81.70M |
| QoQ Change | — | -5.8% | +25.7% | -50.6% | +40.4% | +28.9% | +39.4% | -46.5% | +47.1% | +24.2% | +22.5% | -36.6% |
| YoY Change | — | — | +18.4% | — | — | +12.4% | +24.7% | +35.0% | +41.5% | +36.3% | +19.8% | +42.1% |
Range$42.60M – $128.80M
CAGR+4.3%
Avg YoY Growth+28.8%
Median YoY Growth+29.8%
Accrued Expenses at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's accrued expenses?
- Neurocrine Biosciences (NBIX) reported accrued expenses of $81.70M in Q1 2026.
- How has Neurocrine Biosciences's accrued expenses changed year-over-year?
- Neurocrine Biosciences's accrued expenses increased by 42.1% year-over-year, from $57.50M to $81.70M.
- What is the long-term trend for Neurocrine Biosciences's accrued expenses?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's accrued expenses has grown at a 20.9% compound annual growth rate (CAGR), from $72.80M to $128.80M.
- What does accrued expenses mean?
- Expenses the company has incurred but has not yet received a bill for or paid.